ALK and non-small cell lung carcinoma: Heo et al. [79] employed scRNA-seq analysis in an in vitro model of ceritinib-resistant non-small cell lung cancer (NSCLC) to identify upregulation of cytidine deaminase (CDA) as a primary characteristic of anaplastic lymphoma kinase (ALK) inhibitor resistance.